Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, shares her work looking into the accuracy of bloodbased biomarkers of Alzheimer’s disease. To be clinically effective, bloodbased biomarkers require strong agreement with cerebrospinal fluid (CSF) and positron emission tomography (PET) markers. Currently, several blood tests exist, but most lack the necessary performance level for practical use. Notably, plasma ptau217 appears to demonstrate high accuracy in predicting PET status. A test analyzing the ratio of phosphorylated to nonphosphorylated tau217 (tau217 occupancy) exhibits exceptional accuracy in predicting amyloid PET status. In a cohort of over 300 individuals who underwent amyloid PET and measurement of established CSF biomarkers, classification accuracy was equivalent for plasma tau217 occupancy and CSF Aβ42/Aβ40. Additionally, plasma tau217 occupancy more accurately classified individuals as cognitively impaired versus unimpaired, and better correlated with dementia severity, compared to CSF Aβ42/Aβ40. With diseasemodifying treatments becoming more and more available, knowledge of amyloid status is becoming crucial, influencing distinct management pathways. However, meeting the higher demand for capacity is imperative for broader implementation of bloodbased biomarkers in clinical practice. This interview took place at the Alzheimer's Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.